# TROPION-Lung17 (NCT07291037)

> Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations

No report yet. It can be ordered.

- Drugs tested: datopotamab deruxtecan
- Indication: TROP2-positive advanced/metastatic non-squamous NSCLC without actionable genomic alterations

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT07291037
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: AstraZeneca
- Conditions: Non-small Cell Lung Cancer (NSCLC)
- Interventions: Datopotamab deruxtecan (Dato-DXd); Docetaxel
- Enrollment: 400
- Primary outcome: Progression-free survival (PFS)
- Primary outcome: Overall survival (OS)

## Indexed commentary on TROPION-Lung17 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X
- 2 YouTube videos
- 1 podcast episode

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=tropion-lung17-nct07291037